Asthma Therapeutics in Major Developed Markets Growth & Trend to 2020 Radiant Insights, Inc
Summary Radiant Insights, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence. The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025. Access This Full Report @ http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest. Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
Summary
Radiant Insights, a leading business intelligence provider, has released its latest research report,"Asthma Therapeutics in Major Developed Markets to 2020 - Personalized Treatment for Severe Asthma to Drive Market Growth despite Patent Expirations".The asthma therapeutics market is forecast to grow marginally over the forecast period across the top eight developed nations, from $18.4 billion in 2013 to a projected value of $21.7 billion by 2020 at a Compound Annual Growth Rate (CAGR) of 2.4%. This is in spite of generic erosion facing several of the leading asthma brands, such as Advair (fluticasone propionate/salmeterol xinafoate), Symbicort (budesonide/formoterol fumarate) and Xolair (omalizumab), and is a consequence of new market entrants and rising disease prevalence.
The global prevalence of asthma is significant, believed to affect approximately 300 million people worldwide. This burden is predicted to increase in future, reaching 400 million by 2025.
Access This Full Report @ http://www.radiantinsights.com/research/asthma-therapeutics-in-major-developed-markets-to-2020-personalized-treatment-for-severe-asthma-to-drive-market-growth-despite-patent-expirations
Although the majority of asthma patients are able to manage their symptoms effectively using currently marketed products, some remain inadequately controlled with these same products. This unmet need, coupled with rising global prevalence, has resulted in strong industry interest.
Consequently, the current asthma pipeline is highly innovative, featuring several promising molecules in late-stage drug development. Biologics and monoclonal antibodies, the latter in particular, are gaining prominence within the indication. Novel monoclonal antibodies such as mepolizumab, reslizumab, lebrikizumab, and dupilumab target Interleukins (IL), or IL receptors, and have demonstrated potential in severe and inadequately controlled eosinophilic asthma, in turn representing a shift towards personalized therapy. Despite the fact that they target only a small patient sub-set, they are likely to be priced highly and to drive market growth, offsetting the impact of generic erosion.
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Figure 3: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Pipel<strong>in</strong>e, 2015 45<br />
Figure 4: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Pipel<strong>in</strong>e by Molecular Target, 2015 48<br />
Figure 5: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Pipel<strong>in</strong>e by Molecular Target, Breakdown of<br />
Immune/Inflamma<strong>to</strong>ry System Targets and Cy<strong>to</strong>k<strong>in</strong>e/Cy<strong>to</strong>k<strong>in</strong>e Recep<strong>to</strong>r Targets, 2015 49<br />
Figure 6: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Pipel<strong>in</strong>e by Molecular Target, Breakdown of Enzyme and<br />
K<strong>in</strong>ase Molecular Targets, 2015 51<br />
Figure 7: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Pipel<strong>in</strong>e by Molecular Target, Breakdown of Adrenergic<br />
and Chol<strong>in</strong>ergic Recep<strong>to</strong>rs, 2015 52<br />
Figure 8: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Cl<strong>in</strong>ical Trial Failure Rate, 2006–2014 54<br />
Figure 9: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Cl<strong>in</strong>ical Trial Failure Rate by Molecule Type, 2006–2014<br />
55<br />
Figure 10: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Cl<strong>in</strong>ical Trial Failure Rate by Molecular Target, 2006–<br />
2014 57<br />
Access This Full Report @ http://www.radiant<strong>in</strong>sights.com/research/asthma-therapeutics-<strong>in</strong>major-developed-markets-<strong>to</strong>-<strong>2020</strong>-personalized-treatment-for-severe-asthma-<strong>to</strong>-drive-marketgrowth-despite-patent-expirations<br />
Figure 11: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Cl<strong>in</strong>ical Trial Duration by Stage of Development and<br />
Molecule Type, (months), 2006–2014 59<br />
Figure 12: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Phase I Cl<strong>in</strong>ical Trial Duration by Molecular Target<br />
(months), 2006–2014 60<br />
Figure 13: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Phase II Cl<strong>in</strong>ical Trial Duration by Molecular Target<br />
(months), 2006–2014 61<br />
Figure 14: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Phase III Cl<strong>in</strong>ical Trial Duration by Molecular Target<br />
(months), 2006–2014 62<br />
Figure 15: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Cl<strong>in</strong>ical Trial Recruitment Size by Stage of<br />
Development and Molecule Type for Individual <strong>Asthma</strong> Products (participants), 2006–2014 63<br />
Figure 16: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Cl<strong>in</strong>ical Trial Recruitment Size by Stage of<br />
Development and Molecule Type for Individual <strong>Asthma</strong> Cl<strong>in</strong>ical Trials (participants), 2006–2014 65<br />
Figure 17: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Phase I Cl<strong>in</strong>ical Trial Recruitment Size by Molecular<br />
Target (participants), 2006–2014 67<br />
Figure 18: <strong>Asthma</strong> <strong>Therapeutics</strong> Market, Global, Phase II Cl<strong>in</strong>ical Trial Recruitment Size by Molecular<br />
Target (participants), 2006–2014 68
Change language